S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

from OncLive® On Air · host OncLive® On Air

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

Episode metadata supplied by the publisher feed · Published Jun 15, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

0:00 12:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 12 minutes long.

When was this OncLive® On Air episode published?

This episode was published on June 15, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!